Blake Byers Net Worth

Blake Byers biography

Dr. Blake Byers Ph.D. serves as Independent Director of the Company. Dr. Byers has worked at GV (formerly Google Ventures). As an investor and general partner at GV, Dr. Byers partners with founders of life science and digital companies – from drug development and healthcare delivery to financial services and information security. Dr. Byers served as President of Pact Pharma, Inc. from February 2018 to October 2018 and is currently Chairman of their Board of Directors. Dr. Byers also serves on the Board of Directors of several private companies, including IonQ Inc. and Lime. Prior to joining GV, Dr. Byers helped start two companies, led research projects on biomedical engineering and stem cells at Stanford University and was an angel investor. Dr. Byers received a Ph.D. and M.S. in bioengineering from Stanford University and holds a B.S in biomedical engineering and economics from Duke University. Byers’ experience working in the venture capital industry and history with stem cell technology qualifies him to serve on our Board of Directors.

What is the salary of Blake Byers?

As the Independent Director of Magenta Therapeutics Inc, the total compensation of Blake Byers at Magenta Therapeutics Inc is $197,947. There are 12 executives at Magenta Therapeutics Inc getting paid more, with Christina Isacson having the highest compensation of $2,277,560.

How old is Blake Byers?

Blake Byers is 35, he's been the Independent Director of Magenta Therapeutics Inc since 2017. There are 20 older and no younger executives at Magenta Therapeutics Inc. The oldest executive at Magenta Therapeutics Inc is David Scadden, 67, who is the Independent Director.

What's Blake Byers's mailing address?

Blake's mailing address filed with the SEC is C/O MAGENTA THERAPEUTICS, INC., 100 TECHNOLOGY SQUARE, CAMBRIDGE, MA, 02139.

Insiders trading at Magenta Therapeutics Inc

Over the last 6 years, insiders at Magenta Therapeutics Inc have traded over $6,775,591 worth of Magenta Therapeutics Inc stock and bought 1,257,000 units worth $10,105,000 . The most active insiders traders include Bruce Booth, Rock Ventures Iv, L.P.Third... oraz Jeffrey W. Albers. On average, Magenta Therapeutics Inc executives and independent directors trade stock every 46 days with the average trade being worth of $99,614. The most recent stock trade was executed by Rock Ventures Iv, L.P.Third... on 7 February 2023, trading 3,700,000 units of MGTA stock currently worth $3,071,000.

What does Magenta Therapeutics Inc do?

magenta therapeutics is a biotechnology company harnessing the power of stem cell science to revolutionize stem cell transplantation for patients with immune- and blood-based diseases. by creating a platform focused on key areas of transplant medicine, magenta therapeutics is pioneering an integrated, but modular approach to stem cell therapies that reboot the blood and immune systems to create patient benefit. founded by internationally recognized leaders in stem cell transplant medicine, magenta therapeutics was launched in 2016 by third rock ventures and atlas venture and is headquartered in cambridge, mass. for more information, please visit www.magentatx.com.

Magenta Therapeutics Inc executives and stock owners

Magenta Therapeutics Inc executives and other stock owners filed with the SEC include:

• Christina Isacson,
  Chief Business Officer
• Jason Gardner,
  President, Chief Executive Officer, Co-Founder, Director
• John Davis,
  Chief Medical Officer, Head of Research and Development
• Dr. Jason Gardner Ph.D.,
  Co-Founder, CEO, Pres & Director
• Stephen F. Mahoney J.D., MBA,
  Chief Financial & Operating Officer and Treasurer
• Anne McGeorge,
  Independent Director
• David Scadden,
  Independent Director
• Michael Bonney,
  Independent Chairman of the Board
• Alexis Borisy,
  Independent Director
• Jeffrey Albers,
  Independent Director
• Thomas Daniel,
  Independent Director
• Bruce Booth,
  Independent Director
• Blake Byers,
  Independent Director
• Amy Ronneberg,
  Independent Director
• Steve Mahoney,
  Chief Financial and Operating Officer
• Manisha Pai,
  Vice President - Communications and Investor Relations
• Zoran Zdraveski,
  Secretary and Chief Legal Officer
• Li Malmberg,
  Senior Vice President - Head of Manufacturing
• Kristen Stants,
  Chief People Officer
• Cindy Driscoll,
  Vice President - Finance
• Dr. Jan Pinkas Ph.D.,
  Sr. VP & Head of Translational Sciences
• Catherine Monaghan,
  Head of Clinical Devel. Operations
• Kristen Stants,
  Chief People Officer
• Lyndsey Scull,
  Director of Corp. Communications
• Thomas W. Beetham,
  Chief Legal Officer
• Jim Haney,
  Sr. Director of Investor Relations
• Dr. Lisa M. Olson Ph.D.,
  Head of Research & Chief Scientific Officer
• David Wayne Nichols,
  Chief Technical Officer
• Lisa Olson,
  See Remarks
• Caren Deardorf,
  Chief Commercial Officer
• Venture Fund X, L.P.Atlas V...,
  
• Rock Ventures Iv, L.P.Third...,
  
• 2016 Gp, L.L.C.Gv 2016 Gp, ...,
  
• Jason Ryan,
  See Remarks
• Venture Fund X, L.P. Atlas,
  10% owner
• Stephen F. Mahoney,
  See Remarks
• Michael P. Cooke,
  Chief Scientific Officer
• Thomas W. Beetham,
  See Remarks
• Jeffrey Humphrey,
  Chief Medical Officer
• Alison Frances Lawton,
  Director
• David Wayne Nichols,
  Chief Technical Officer
• Michael Vasconcelles,
  Director